AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, ...

Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...

AbbVie is a Dividend King that's quickly moving past reliance on Humira. Enbridge shouldn't be affected by potential Canadian ...

February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three ...

Just as Andrew Witty of UnitedHealth Group did in a call with investors last month, CVS Health’s CEO David Joyner defended ...

AbbVie made a change atop its board of directors, naming CEO Robert Michael as chairman on Friday morning. The pharma giant announced that Michael will succeed Richard A. Gonzalez, the former CEO of ...

The past couple of years have been tumultuous for AbbVie. The company lost patent exclusivity for its best-selling drug, ...

We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going ...

SmithRx's 2024 growth comes with continued validation of its transparent, 100% pass-through model, which helps significantly lower costs for employer clients. Paired with Connect 360's innovative ...

Yet, their place and cost remain fairly misunderstood. For over a decade, Humira has been the highest-grossing drug in the world, bringing in some $21 billion for manufacturer AbbVie in 2021.

Alvotech has developed a biosimilar of Humira called AVT02, the first-filed biosimilar drug equal in strength to Humira’s latest formulation, which AbbVie markets as a high-concentration, pain ...

That’s why one of the most closely watched elements of a company’s earnings report is the guidance it gives for the next ...